GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Enterprise Value

Nascent Biotech (Nascent Biotech) Enterprise Value : $16.06 Mil (As of May. 27, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nascent Biotech's Enterprise Value is $16.06 Mil. Nascent Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.16 Mil. Therefore, Nascent Biotech's EV-to-EBIT ratio for today is -13.83.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Nascent Biotech's Enterprise Value is $16.06 Mil. Nascent Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.16 Mil. Therefore, Nascent Biotech's EV-to-EBITDA ratio for today is -13.83.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Nascent Biotech's Enterprise Value is $16.06 Mil. Nascent Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Nascent Biotech's EV-to-Revenue ratio for today is .


Nascent Biotech Enterprise Value Historical Data

The historical data trend for Nascent Biotech's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Enterprise Value Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Enterprise Value
Get a 7-Day Free Trial 5.42 12.17 6.66 6.25 7.63

Nascent Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.32 7.63 7.44 20.28 28.67

Competitive Comparison of Nascent Biotech's Enterprise Value

For the Biotechnology subindustry, Nascent Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Enterprise Value falls into.



Nascent Biotech Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Nascent Biotech's Enterprise Value for the fiscal year that ended in Mar. 2023 is calculated as

Nascent Biotech's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nascent Biotech  (OTCPK:NBIO) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Nascent Biotech's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=16.060/-1.161
=-13.83

Nascent Biotech's current Enterprise Value is $16.06 Mil.
Nascent Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Nascent Biotech's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=16.060/-1.161
=-13.83

Nascent Biotech's current Enterprise Value is $16.06 Mil.
Nascent Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Nascent Biotech's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=16.060/0
=

Nascent Biotech's current Enterprise Value is $16.06 Mil.
Nascent Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nascent Biotech Enterprise Value Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech (Nascent Biotech) Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121